07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Horizant gabapentin enacarbil: Phase II started

XenoPort said NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA) began the double-blind, placebo-controlled, U.S. Phase II NCIG-006 trial to evaluate 600 mg oral Horizant twice daily for 26 weeks in about 350 patients....
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Horizant gabapentin enacarbil update

XenoPort and the Willis-Ekbom Disease (WED) Foundation began the Patient Odyssey survey in patients with RLS to evaluate challenges of long-term disease management, quality of life, emotional burden associated with RLS and impact on relationships...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Calcium channel N-type; calcium channel P/Q-type Cell-based and mouse studies identified an agonist...
07:00 , Jun 16, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Collapsin response mediator protein-2 (DPYSL2; CRMP-2); calcium channel N-type Mouse studies...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Clinical News

Horizant gabapentin enacarbil: Phase IIb data

Top-line data from a 30-week, double-blind, dose-ranging, North American Phase IIb trial in 526 patients showed that gabapentin enacarbil missed the primary endpoint of significantly reducing the number of migraine headache days during the last...
07:00 , Oct 12, 2009 |  BC Week In Review  |  Clinical News

XP13512: Phase II data

Top-line data from a double-blind, crossover Phase II trial in 96 evaluable patients showed that 3,600 mg/day Solzira met the primary endpoint of significantly reducing 24-hour average pain intensity score from baseline to the end...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Clinical News

Solzira: Phase IIb data

Top-line data from a 14-week, double-blind Phase IIb trial in 376 PHN patients showed that 1,200, 2,400 and 3,600 mg/day Solzira met the primary endpoint of significantly reducing the 24-hour average pain intensity score from...